152 related articles for article (PubMed ID: 30881166)
1. Differential response to a combination of full-dose osimertinib and crizotinib in a patient with
Zhu VW; Schrock AB; Ali SM; Ou SI
Lung Cancer (Auckl); 2019; 10():21-26. PubMed ID: 30881166
[TBL] [Abstract][Full Text] [Related]
2. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Wang Y; Tian P; Xia L; Li L; Han R; Zhu M; Lizaso A; Qin T; Li M; Yu B; Mao X; Han-Zhang H; He Y
Lung Cancer; 2020 Aug; 146():165-173. PubMed ID: 32540560
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
4. Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.
Blasi M; Kazdal D; Thomas M; Christopoulos P; Kriegsmann M; Brandt R; Volckmar AL; Kirchner M; Heußel CP; Stenzinger A; Kuon J
Case Rep Oncol; 2021; 14(1):477-482. PubMed ID: 33976623
[TBL] [Abstract][Full Text] [Related]
5. A rapid and durable response to cabozantinib in an osimertinib-resistant lung cancer patient with
Kuang Y; Wang J; Xu P; Zheng Y; Bai L; Sun X; Li Z; Gan R; Li H; Ke Z; Tang K
Ann Transl Med; 2021 Aug; 9(16):1354. PubMed ID: 34532491
[TBL] [Abstract][Full Text] [Related]
6. Successful crizotinib monotherapy in
Yoshimura K; Inui N; Karayama M; Inoue Y; Enomoto N; Fujisawa T; Nakamura Y; Takeuchi K; Sugimura H; Suda T
Respir Med Case Rep; 2017; 20():160-163. PubMed ID: 28271038
[No Abstract] [Full Text] [Related]
7. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic
Cai B; Li X; Huang X; Ma T; Qu B; Yu W; Yang W; Zhang P; Chen J; Liu F
Front Oncol; 2021; 11():738832. PubMed ID: 34926253
[TBL] [Abstract][Full Text] [Related]
9. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
10. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.
Wang K; Du R; Roy-Chowdhuri S; Li ZT; Hong L; Vokes N; Elamin YY; Hume CB; Skoulidis F; Gay CM; Blumenschein G; Fossella FV; Tsao A; Zhang J; Karachaliou N; O'Brate A; Gann CN; Lewis J; Rinsurongkawong W; Lee JJ; Gibbons DL; Vaporciyan AA; Heymach JV; Altan M; Le X
JTO Clin Res Rep; 2023 Aug; 4(8):100533. PubMed ID: 37649681
[TBL] [Abstract][Full Text] [Related]
11. A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance.
Liu L; Qu J; Heng J; Zhou C; Xiong Y; Yang H; Jiang W; Zeng L; Zhu S; Zhang Y; Tan J; Hu C; Deng P; Yang N
Front Oncol; 2021; 11():722039. PubMed ID: 34660287
[TBL] [Abstract][Full Text] [Related]
12. Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.
Zheng X; Zhang G; Li P; Zhang M; Yan X; Zhang X; Yang J; Li H; Liu X; Ma Z; Wang H
Lung Cancer; 2019 Mar; 129():72-74. PubMed ID: 30797494
[TBL] [Abstract][Full Text] [Related]
13. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.
Jóri B; Vössing C; Pirngruber J; Willing EM; Arndt K; Falk M; Tiemann M; Heukamp LC; Hoffknecht P
Curr Oncol; 2023 Sep; 30(10):8805-8814. PubMed ID: 37887535
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
15. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
16. Targeting
Aboubakar Nana F; Ocak S
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575554
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon
Ou L; Tang Y; Deng Y; Guo L; He Q; He T; Feng W
Front Oncol; 2022; 12():911362. PubMed ID: 35957915
[TBL] [Abstract][Full Text] [Related]
18. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report.
Liu Z; Song P; Zhou L; Ji D; Shen H; Dong H; Feng X
Cancer Manag Res; 2023; 15():645-650. PubMed ID: 37465082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
